FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism Three pivotal trials showed PRADAXA as ...
The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency ...
The Food and Drug Administration (FDA) has grated accelerated approval to Praxbind (idarucizumab; Boehringer Ingelheim) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during ...
The most common side effects of Pradaxa (dabigatran) include gastrointestinal problems like nausea, diarrhea, AND abdominal pain. Excessive bleeding is also a common side effect of Pradaxa. In some ...
Abstract sphere from a blood clot cells background. Scientific and medical microbiological concept. Enrichment with oxygen and important nutrients. Transfer of important elements, 3d illustration ...
A weekly update on new drug approvals and indications from the US Food and Drug Administration (FDA). Pradaxa gets new indication as oral therapy for VTE in children Boehringer Ingelheim’s Pradaxa ...
Boehringer Ingelheim is accusing The British Medical Journal (BMJ) of making “misleading statements” after the journal published an article and an editorial critical of the company’s pursuit of ...
The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback